Does Coenzyme Q 10 Supplementation Reduce Muscle Pain Caused by Statins? (Cholesterol Lowering Medications)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether Coenzyme Q 10 supplementation will decrease the rate of Muscle Pain in patients with previous statin related Muscle Pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Benefit of CoQ-10 in Patients on Statins

NCT00997269

Pain Soreness Weakness +1 more

COMPLETED NA

The Effect of Q10 and Selen Supplement on Muscular Adverse Events in Statin Therapy

NCT00113477

Statin Therapy

COMPLETED PHASE4

CoQ10 in Statin-associated Asthenia

NCT06391606

Hypercholesterolemia Physical Performance

COMPLETED NA

Coenzyme Q10 in Relation to the Antioxidative Vitamins, Oxidative Stress and Inflammation in Coronary Artery Disease Patients During Statin Therapy

NCT01424761

Coronary Artery Disease

COMPLETED PHASE2/PHASE3

Quercetin for Cardio-Skeletal Muscle Health and Estrogen Deficiency

NCT04258410

Menopause Related Conditions

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Statin Induced Myalgia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2

PO Placebo QD

Group Type PLACEBO_COMPARATOR

Placebo control

Intervention Type DRUG

po Placebo QD

1

PO Coenzyme Q 10 QD

Group Type EXPERIMENTAL

Coenzyme Q 10

Intervention Type DRUG

PO Coenzyme Q 10 120 mg QD

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Coenzyme Q 10

PO Coenzyme Q 10 120 mg QD

Intervention Type DRUG

Placebo control

po Placebo QD

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ubiquinone

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients treated for hyperlipidemia with a HMG-CoA reductase inhibitor (i.e. pravastatin, simvastatin rosuvastatin or atorvastatin) and reporting myopathic symptoms

Exclusion Criteria

* Patients with other identifiable cause of myopathy. Patients with clinical evidence of hepatic, renal, or endocrine disease; coagulopathy; or other serious medical conditions will be excluded.

Minimum Eligible Age

20 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No